Lyell Immunopharma is a clinical-stage biopharmaceutical company dedicated to developing innovative cell-based immunotherapies to conquer T-cell exhaustion and solve primary obstacles in the treatment of solid tumors and cancer. The company utilizes proprietary technology platforms designed to program and control T cells, ensuring they maintain functionality and potency after being administered to patients. By focusing on advanced cellular reprogramming and genetic modifications, Lyell aims to significantly improve the efficacy and persistence of adoptive cell therapies for hard-to-treat oncological indications.